Bryan, Garnier & Co makes significant move into the Nordics with the acquisition of Beringer Finance
Bryan, Garnier & Co combines with Nordic growth investment bank Beringer Finance, further strengthening the firm’s leadership in the European investment banking landscape.
- The group expands its European footprint with the addition of offices in Stockholm, Oslo and Reykjavik. Bryan, Garnier & Co will also add the current Beringer Finance Palo Alto office to its existing US presence in NYC.
- CEO Adalsteinn Johannsson will join Bryan, Garnier & Co as Partner focused on International M&A, with Beringer’s Tor Berthelius as Partner to lead the Nordic operations.
- The combination reinforces the group with 31 professionals focused on Technology, IT Services and Fintech.
- Beringer has conducted more than 140 M&A, ECM and Private Placements transactions in the past 10 years alone, and benefits from a leading position in the Nordic markets.
- The combination provides a strong foothold for the firm to expand its leading European Life-Sciences practice in the Nordics.
[London, Paris, Munich] — Wednesday 17th April, 2019. Today, Bryan, Garnier & Co announced the acquisition of Beringer Finance and the expansion of its partnership. Beringer Finance is a premier, Nordic-focused boutique investment bank with offices in Stockholm, Oslo, Reykjavik and Palo Alto. Throughout the past 10 years, Beringer Finance has advised on over 140 transactions, building a strong track record in the TMT, IT Services, and Fintech markets. The closing is subject to pending regulatory approvals and other customary closing conditions.
Olivier Garnier, Co-founder and Managing Partner of Bryan, Garnier & Co comments: “Bryan, Garnier & Co is an independent partnership that combines highly experienced, entrepreneur-minded investment banking professionals with the services and expertise of a top-tier investment bank. The culture of excellence at Beringer Finance and our shared ambition to expand will be a strong driver to accelerate Bryan, Garnier & Co’s development in the region, across our business lines and industry sectors. We are delighted to welcome Adalsteinn Johannsson and his team to lead this effort”.
“The Nordics is one of the main European Technology and Life Sciences hubs where we have longstanding client relationships” comments Greg Revenu, Managing Partner of Bryan, Garnier & Co. “This combination not only creates an exciting opportunity for the firm and its teams, but also a unique capacity to support the growth of our clients: it propels our Technology coverage to the next level, while opening a new challenge to our leading European healthcare franchise.”
“We are excited to be joining forces with Bryan, Garnier & Co” explains Adalsteinn Johannsson, CEO at Beringer Finance. “Its full-service capacities combining investment banking and capital markets services provides us with the scale and resources to accelerate our growth. Bryan, Garnier & Co’s entrepreneurial DNA is a perfect match for the strong culture and unique approach we have built at Beringer. We very much look forward writing this journey together with this outstanding team.”
Beringer Finance will be operating under the Bryan, Garnier & Co brand with CEO Adalsteinn Johannsson joining Bryan, Garnier & Co as a partner focused on International M&A, with Beringer’s Tor Berthelius as a partner to lead the Nordic operations. Beringer’s 27 technology-focused bankers will be fully integrated with Bryan, Garnier & Co’s existing investment banking professionals, across its London, Paris, Munich, Stockholm, Oslo, Reykjavik, New York and Palo Alto offices. With a European technology group of more than 80 professionals, Bryan, Garnier & Co will benefit from an unmatched position in the European technology investment banking landscape.
RECENT ACHIEVEMENTS
Over the past 24 months, Bryan, Garnier & Co and Beringer Finance have led more than 85 transactions, including backing three of the most disruptive unicorns of 2018:
- 47 international public and private M&A deals representing an aggregate value of approximately $2.4 billion, many of which involved tier one private equity investors and publicly-listed trade buyers. Recent deals include the sale of Sword Apak to Sopra Banking Software, the sale of Symetis to Boston Scientific for $435m, the sale of Dimelo to RingCentral, the sale of Prima Solutions to the Carlyle Group, the 30% sale of Advania to VIA equity and PFA, and the sale of Universum to Axel Springer company StepStone.
- 25 growth capital private placements and PIPEs representing an aggregated amount raised of some $550 million, for companies such as blockchain unicorn Bitfury ($80m), biotech unicorn Moderna ($80m), Tado° ($50m), Highlife ($37m), Devialet ($210m), and BraBank ($35m).
- 15 IPOs and public offerings on Nasdaq, NYSE, Euronext, and other major exchanges for an aggregated amount of more than $1.4 billion, including four deals led or co-led on Nasdaq or NYSE. Recent transactions include: representation of cannabis unicorn Canopy Growth ($450m, TMX, NYSE), Medartis ($138m, Swiss Exchange), Materialise ($52m, Nasdaq), Medigene ($56m, Deutsche Börse Group), Celyad ($53m, Nasdaq, Euronext) and Genfit ($155.4m, Nasdaq).
About Beringer Finance
Beringer Finance is a technology focused boutique investment bank with offices in Stockholm, Oslo, Reykjavik and Palo Alto. Tracing its roots back over 100 years, Beringer is continuously driven by the ambition to help companies and entrepreneurs strategically develop and grow their businesses while realizing their dreams and their aspirations.
Their expertise and market leadership have seen them advise top-tier clients on over 140 transactions in the past 10 years. Despite calling the Nordics its home, Beringer works across all continents and focuses on M&A and private placements after selling its Fondsfinans brokerage business in 2018.
The new big data world
The convergence of cloud computing, big data, IOT and artificial intelligence has transformed the database industry. Although relational databases still dominate, newer technologies such as Hadoop, NoSQL and NewsSQL are driving waves of acquisition and consolidation. While Oracle and Amazon fight over the #1 spot, there are also plenty of potential unicorns in the sector.
Download report
European Investment Bank Bryan, Garnier & Co names new Partner in ECM
PARIS, LONDON, MUNICH, NEW YORK: 20 February, 2019 – Bryan, Garnier & Co, a leading pan-European investment banking partnership focusing on growth companies, today announces that Pierre Kiecolt-Wahl is to become a Partner at the firm.
Pierre Kiecolt-Wahl, a dual American/French citizen joined Bryan, Garnier & Co’s European investment banking team as Managing Director, heading up the Equity Capital Markets division in May 2016. Pierre brings over 15 years of international equity capital markets knowledge with organizations such as Bank of America, Lehman Brothers, Jefferies and Citi, based in San Francisco, London and Hong Kong.
Since arriving at Bryan, Garnier & Co, he has led numerous transactions, continuing to strenghthen the firm’s footprint across Europe and the US. Key transactions include: Zealand Pharma Wall-Crossed Follow-On Offering (DKK 143m) | Symetis Euronext IPO & subsequent sale to Boston Scientific ($435m), Celyad Nasdaq & Euronext Publicly Marketed Follow-on Offering (€46m) | Ablynx Nasdaq IPO ($230m) | Medartis Six Swiss IPO (CHF 143m) | Canopy Growth Global Convertible Bond, Toronto Stock Exchange (CAD 600m) and Materialise’s Nasdaq Follow-on Offering ($45m).
Olivier Garnier, Co-founder & Managing Partner comments: “We are excited to welcome Pierre into the Bryan Garnier partnership, one of the few remaining independent investment banking partnerships in Europe. This makes us very special. Since founding the bank over 22 years ago, our business model has created a strong entrepreneurial culture that truly aligns us with the interest of our clients which Pierre has embraced. The personal commitment of our partners to the firm ensures a long-term perspective in building Bryan, Garnier & Co and our clients know they can count on us to stay the course with them as their business grows. We would like to congratulate Pierre for becoming Partner to Bryan, Garnier & Co. This is a very exciting time for the firm and we wish Pierre every success in his new role.”
2018 in retail: engaging with the connected consumer
At our fourth Consumer, Brands & Retail Conference on 24-25 September 2018, Bryan, Garnier & Co analysts were joined by many companies active in the sector. Three thematic roundtables covered some of the sector’s most pressing issues: the future of the point of sale, millennials activation and the impact of
artificial intelligence.
Download report
Transforming the R&D industry
As the outsourced R&D and engineering services market continues to grow, we look at the trends shaping this dynamic market, from globalization and concentration to hybrid business models and evolving client demands. For the key players, size is becoming increasingly important in a market where scale matters.
Download report
Bryan, Garnier & Co strengthens its Healthcare team with the hiring of Jean-Jacques Le Fur as Senior Financial Analyst
PARIS, August 28, 2018 – Bryan, Garnier & Co, the leading pan-European Investment Bank focusing on growth companies, is delighted to welcome Jean-Jacques Le Fur to its European Healthcare team.
With over 20 years of experience as a sell side analyst in European pharmaceuticals, Jean-Jacques will join the Healthcare team as an analyst and will help Bryan, Garnier & Co to leverage its footprint within the Healthcare sector.
Before joining Bryan, Garnier & Co, Jean-Jacques was a senior Pharmaceutical analyst at Oddo-BHF and Natixis. Before life as an analyst, he held various positions in R&D and Finance at Hoechst-Marion-Roussel and Ipsen.
Eric Le Berrigaud, Managing Partner in Paris comments: “I have known Jean-Jacques for many years and I am delighted to have him join us to take our already very successful healthcare practice to the next level. The new team will have the objective of covering more companies across all segments, increasing the number of client events as well actively being involved in more transactions.”
Jean-Jacques Le Fur adds: “Bryan Garnier & Co is a leader in the Healthcare sector combining stock market and banking services with an entrepreneurial culture. I look forward to contributing to the continued development of the Healthcare team and transforming ideas into opportunities for our clients.”
Jean-Jacques holds a degree in Pharmacy (PharmD) from Paris University as well as an MBA, from IAE, Paris.
Luxury goods e-commerce, back to the future
E-commerce is set to be the fastest growing channel until 2025 with a strong pace of growth – at 20%, within the luxury goods market growing by 4%-5%, and thus generating 43% of the luxury goods market growth. At luxury goods firms, e-commerce looks set to undergo the same transformation that their physical operations saw in the 2000s. This means more ‘retail’ digital business models, with more direct control by brands. In this paper, we examine how this shift might play out and what it means for the luxury industry and groups.
Download report
Bryan, Garnier & Co strenghtens its Business Services team with the hiring of Marc Picard as Executive Advisor
PARIS, March 13, 2018 – Bryan, Garnier & Co, the leading pan-European Investment Bank focusing on growth companies, is delighted to welcome Marc Picard to its European Business Services team.
With over 20 years of experience in global finance including 17 years in M&A, Marc will participate in the development of mid-market deals, in particular family-owned businesses, as well as help Bryan, Garnier & Co leverage its footprint within the business service sector. He will be based in Paris.
Before joining Bryan, Garnier & Co, Marc worked at HSBC France for five years and then joined Ernst & Young where he finally co-led the M&A team across various activities including: Distribution, Recycling, Facility Management, Building and Public works and Real Estate. During this time, Marc assisted numerous mid-market private companies in securing capital for growth.
Guillaume Nathan, Partner, Business Services Practice, Paris comments: "I am delighted to have Marc join Bryan, Garnier & Co to help us in developing our Business Services Practice. Thanks to his deep knowledge of the industry and close relationship with some key players, we are already engaged in some visible transactions".
Marc Picard adds: "Bryan, Garnier & Co is a high performing European financial services firm with an extensive access to the American market through his partnership with JMP. The combination of a fully integrated investment bank with a broad geographical presence and a deep specialization in Business Services give us a unique means to help our clients achieve ambitious goals. I am pleased to support the team in developing the Business Services line".
Marc holds a Master’s Degree in Political Sciences from Sciences Po Paris where he majored in Economics and Finance.
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo and Reykjavik as well as New York and Palo Alto. The firm is a member of the London Stock Exchange.
CES 2018 - artificial intelligence takes control
At this year’s Consumer Electronics Show in Las Vegas it was all about the “cockpit of the future” and AI. In this report we round up the most significant developments in the auto and semiconductor industries that we saw during our visit to CES 2018.
Advancing therapies: review of the most important oncology and haematology treatments in 2017
In our latest healthcare white paper, we review game-changing developments in oncology and haematology treatments, with a specific focus on immuno-oncology drugs and CAR-T therapies.